US Patent 11292842 Anti-PD-1 antibodies for treatment of lung cancer
Patent 11292842 was granted and assigned to Regeneron Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
February 20, 2018
Date of Patent
April 5, 2022
Patent Applicant
Patent Application Number
16486688
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11292842 Anti-PD-1 antibodies for treatment of lung cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
